News Detail

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Benzinga · 10/02 12:24

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

BMO Capital analyst Joel Jackson initiated coverage on Vylor, Inc. (NYSE:VYLR) with an Outperform rating and announced a price target of $85. Vylor closed at $68.26 on Thursday. See how other analysts view this stock.
Needham analyst Ami Fadia initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with a Buy rating and announced a price target of $68. LB Pharmaceuticals shares closed at $37.28 on Thursday. See how other analysts view this stock.
Morgan Stanley analyst Sean Laaman initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN) with an Overweight rating and announced a price target of $70. Enliven Therapeutics closed at $46.21 on Thursday. See how other analysts view this stock.
Keybanc analyst Eric Heath initiated coverage on Sailpoint Inc (NASDAQ:SAIL) with a Sector Weight rating. SailPoint shares closed at $20.58 on Thursday. See how other analysts view this stock.
Raymond James analyst Tiago Fauth initiated coverage on Avalyn Pharma Inc (NASDAQ:AVLN) with an Outperform rating and announced a price target of $60. Avalyn Pharma closed at $27.42 on Thursday. See how other analysts view this stock.

Considering buying ELVN stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.